DiscoverMind Medicine#12 - Lars Wilde: Scaling The Model For Psilocybin-Assisted Psychotherapy
#12 - Lars Wilde: Scaling The Model For Psilocybin-Assisted Psychotherapy

#12 - Lars Wilde: Scaling The Model For Psilocybin-Assisted Psychotherapy

Update: 2021-07-161
Share

Description

Lars Wilde is the President, Chief Business Officer, and Co-founder of COMPASS Pathways.


COMPASS is a UK life sciences company that works to expedite the approval and delivery of mental health therapies to patients and focuses primarily on testing psilocybin for use in patients with treatment-resistant depression (TRD). They have 22 trials running through the US and Europe for TRD.


In this episode:

  • Personal journey and battles with anxiety, and seeking psychiatric help
  • The subjective experience of psilocybin and impact of emotional processing and cognitive function
  • Birth of COMPASS
  • The current landscape of the research
  • Models for therapies and how they can scale
  • Research questions that need to be addressed
  • COMPASS decision to patent psilocybin (and what this means for its scientific exploration)
  • Rescheduling psilocybin


Links:

COMPASS Pathways


Support the podcast:

Support the podcast (Patreon)


Support the mission:

Mind Medicine Australia

Donate to Mind Medicine Australia

Join a local chapter



Support this show http://supporter.acast.com/mind-medicine-australia.



Our GDPR privacy policy was updated on August 8, 2022. Visit acast.com/privacy for more information.

Comments 
In Channel
loading
Download from Google Play
Download from App Store
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

#12 - Lars Wilde: Scaling The Model For Psilocybin-Assisted Psychotherapy

#12 - Lars Wilde: Scaling The Model For Psilocybin-Assisted Psychotherapy